SpecialtiesQuestion

How do you assess for flare of giant cell arteritis in a patient on tocilizumab where inflammatory markers may be suppressed by TCZ?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

In a patient with recurrent episodes of GCA that flare shortly after steroid tapering, how do you differentiate between steroid-dependent inflammatory relapse, an alternative autoimmune vasculitic process, and a paraneoplastic phenomenon?

What strategies do you use when initiating treatment for complex livedoid vasculitis in a patient you cannot follow long-term, especially when therapy is limited to conservative measures due to medication contraindications?

How would you approach induction therapy for EGPA with neurological involvement in a middle-aged patient with foot drop and axonal peripheral neuropathy on EMG, but otherwise no evidence of GI/renal/cardiovascular involvement?

How often do you monitor LFTs when starting Avacopan?

How do you manage a patient with GCA who is tapering Prednisone with resolution of inflammatory markers but with slight up trending of ESR/CRP but no symptoms?

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.